Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > Glad to be here.

<< Previous

Bullboard Posts

Next >>

Comment by LuckyExtraon Dec 09, 2020 1:23pm

284 Views

Post# 32068651

RE:RE:RE:Glad to be here.

Will MMED be on the TSX as well? Was wondering if my shares would be converted to US which then my TFSA would be exposed to US withholding tax? I'm not exactly sure how it works but am certainly not excited about it if that is the case. Anybody know?

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China